FDA Accepts New Drug Application for IRLAB’s Mesdopetam for Dyskinesia
The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug application for mesdopetam (IRL790), an experimental therapy for reducing levodopa-induced dyskinesia, or involuntary movements, in people with Parkinson’s disease. This move by the FDA will allow for the enrollment of U.S. patients in…